Recently, the Medical Department V of Fuda Cancer Hospital celebrated exciting academic achievements. A clinical research paper, “A Case of Complete Clinical Remission of Advanced Esophagogastric Junction Adenocarcinoma Treated with Percutaneous Arterial Infusion Chemotherapy Combined with a PD-1 Inhibitor”, co-authored by Director Liu Shupeng, Dr. Deng Bo, and Dr. Zhang Xiao, has been officially accepted by Chinese Journal of Clinical Oncology, one of China’s most authoritative core journals.
Chinese Journal of Clinical Oncology was founded in 1963 by Professor Jin Xianzai, known as the “Father of Oncology in China.” Its current Editor-in-Chief is Academician Hao Xishan, a renowned oncologist, and its Executive Editor-in-Chief is Professor Hao Jihui, President of Tianjin Medical University Cancer Institute & Hospital. With the mission of “guiding innovation, focusing on the frontier, emphasizing clinical practice, and pursuing practicality,” the journal is dedicated to promptly publishing innovative oncological research and advanced clinical experience from both China and abroad. It plays a leading role in discipline development, academic exchange, and clinical practice guidance, ultimately promoting public health.
The paper reports in detail the successful multidisciplinary treatment of a 58-year-old male patient with advanced esophagogastric junction adenocarcinoma. The patient, presenting with swallowing difficulties and rapid weight loss, was diagnosed with low PD-L1 expression esophagogastric junction adenocarcinoma, accompanied by multiple mediastinal and retroperitoneal lymph node metastases—a highly complex condition.
The medical team adopted an innovative treatment strategy of arterial infusion chemotherapy combined with tislelizumab (a PD-1 inhibitor). After eight cycles of combined therapy, the patient achieved clinical complete remission: imaging showed significant tumor shrinkage, and tumor markers returned to normal levels.
From topic selection to final draft, the paper underwent multiple rounds of revisions, with meticulous attention to structure, data analysis, and detailed presentation. With its rigorous academic standards, it successfully gained recognition from a prestigious core journal. The publication provides valuable clinical experience in the treatment of advanced esophagogastric junction adenocarcinoma and demonstrates the comprehensive strength of Department V in clinical translation and team collaboration.
At the same time, the second edition of “Ultra-Low Temperature Cryoablation Technology for Tumors”, published by People’s Medical Publishing House, has been officially released. The book is edited by Professor Wang Hongwu, with Vice President Niu Lizhi and other leading experts serving as associate editors. Written by more than 50 authoritative specialists across China, it integrates the latest international guidelines and technological advances, emphasizing standardized clinical procedures and practical outcomes. Many experts from Fuda Cancer Hospital participated deeply in its compilation, highlighting the hospital’s academic leadership and clinical influence in the field of minimally invasive oncology.
As a National Key Clinical Specialty (Oncology) hospital, Fuda Cancer Hospital will continue to uphold the principle of “developing the hospital through science and technology,” strengthening innovation in both scientific research and clinical practice, and consistently injecting new vitality into the advancement of cancer diagnosis and treatment.